Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial

Overview of attention for article published in Nature Medicine, March 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 36 news outlets
blogs: 3 blogs
twitter: 40 X users
facebook: 1 Facebook page

wikipedia: 1 Wikipedia page
video: 1 YouTube creator
bluesky: 5 Bluesky users

Readers on

mendeley: 95 Mendeley

So far, Altmetric has seen 4 posts from 3 blogs.

2025 Recap: Regenerative Medicine News Under the Microscope

Signals Blog, 12 Mar 2026

A CCRM scientist looking through a…

Regenerative Medicine News Under the Microscope – Spring Edition

Signals Blog, 16 May 2025

In this edition of RMNU🔬, we’re keeping up with multiple research advances in the vision repair field. Also, Vertex…

Stem Cells for Alzheimer’s? Neurologists Weigh In on Longeveron’s New Data

Being Patient, 08 May 2025

Since their discovery in the 1960s, stem cells have captivated our curiosity. Unlike other cells in the body, stem cells are…

Allogeneic Mesenchymal Stem Cell Therapy with Laromestrocel in Mild Alzheimer’s Disease: A Randomized Controlled Phase IIa Trial

Stemcell science news, 10 Mar 2025

Scientists conducted a randomized, double-blind, placebo-controlled, parallel-group Phase IIa clinical trial that tested the…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.